# Abeona: Zevaskyn revenue rises 31% to $11.4M in Q2 2026; 12 patients treated since launch

Canonical page: https://technooptimist.io/stories/abeona-zevaskyn-revenue-rises-31-to-11-4m-in-q2-2026-12-patients-7afd710c
Date: 13 Aug 2026
About: [Abeona Therapeutics](https://technooptimist.io/companies/abeona-therapeutics.md) · [Zevaskyn (pz-cel)](https://technooptimist.io/biotech/zevaskyn.md)
Original source: https://www.1stoncology.com/blog/?p=112851

Abeona reported $11.4M of Zevaskyn revenue in Q2 2026, up from $8.7M in Q1, with five patients treated in the quarter and 12 since launch. New treatment centres at Columbia, CHOP and Cincinnati Children's came online. Manufacturing remains the constraint: one Q2 batch produced too few sheets, and two treatments since launch could not be billed.

## Key facts

- Q2: 5 patients treated, 4 recognised as revenue; 3 more treated in Q3 to date.
- Medicare NTAP add-on payment effective 1 Oct 2026.
- Cash and investments $146.8M at 30 Jun 2026; Q2 net loss $20.2M.

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.